Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

Clinical trial NCT07332507 · RECRUITING

Trial details

NCT number: NCT07332507
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Plasmablastic Lymphoma Refractory Plasmablastic Lymphoma

Start date: 2027-03-26
Primary completion: 2027-12-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.